Nanocarriers for anticancer drugs: Challenges and perspectives

Alqosaibi, Amany I.

doi:10.1016/j.sjbs.2022.103298

Cited by 36 publications

(14 citation statements)

References 127 publications

(132 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Various anticancer drugs are available to treat cancer, but these drugs pose restrictions in therapeutic efficacy for treatment of cancer due to various reasons, such as non-specific treatment, higher adverse effects, required higher doses, small half-life, wide biological distribution, drug resistance, drug instability and lack of drug targeting [ 25 ]. These drugs destroy non-cancerous cells along with cancerous cells at a high pace, leading to severe adverse effects, which are a major cause of the increased death rate among cancer patients.…”

Section: Hindrances In Cancer Treatment By Conventional Drugsmentioning

confidence: 99%

Codelivery of Phytochemicals with Conventional Anticancer Drugs in Form of Nanocarriers

et al. 2023

View full text Add to dashboard Cite

Anticancer drugs in monotherapy are ineffective to treat various kinds of cancer due to the heterogeneous nature of cancer. Moreover, available anticancer drugs possessed various hurdles, such as drug resistance, insensitivity of cancer cells to drugs, adverse effects and patient inconveniences. Hence, plant-based phytochemicals could be a better substitute for conventional chemotherapy for treatment of cancer due to various properties: lesser adverse effects, action via multiple pathways, economical, etc. Various preclinical studies have demonstrated that a combination of phytochemicals with conventional anticancer drugs is more efficacious than phytochemicals individually to treat cancer because plant-derived compounds have lower anticancer efficacy than conventional anticancer drugs. Moreover, phytochemicals suffer from poor aqueous solubility and reduced bioavailability, which must be resolved for efficacious treatment of cancer. Therefore, nanotechnology-based novel carriers are employed for codelivery of phytochemicals and conventional anticancer drugs for better treatment of cancer. These novel carriers include nanoemulsion, nanosuspension, nanostructured lipid carriers, solid lipid nanoparticles, polymeric nanoparticles, polymeric micelles, dendrimers, metallic nanoparticles, carbon nanotubes that provide various benefits of improved solubility, reduced adverse effects, higher efficacy, reduced dose, improved dosing frequency, reduced drug resistance, improved bioavailability and higher patient compliance. This review summarizes various phytochemicals employed in treatment of cancer, combination therapy of phytochemicals with anticancer drugs and various nanotechnology-based carriers to deliver the combination therapy in treatment of cancer.

show abstract

Section: Hindrances In Cancer Treatment By Conventional Drugsmentioning

confidence: 99%

Codelivery of Phytochemicals with Conventional Anticancer Drugs in Form of Nanocarriers

et al. 2023

View full text Add to dashboard Cite

show abstract

“…In addition, several stimuli-responsive alginate-based drug delivery systems have been designed in which the drug release could be stimulated by external non-invasive signals such as light, heat, ultrasound, and magnetic fields [ 18 , 64 ]. Among these strategies, active targeting and stimuli-responsive release behaviors have been mostly focused by researchers to prevent or reduce the off-target effects, undesirable biodistribution, and low therapeutic efficacy [ 66 ]. In this context, dense extracellular matrix as one of the crucial barriers obstructs the penetration of drugs into tumor parenchyma, which can affect the therapeutic efficacy [ 54 ].…”

Section: Challenges and Future Perspectivesmentioning

confidence: 99%

Alginate-Based Micro- and Nanosystems for Targeted Cancer Therapy

Iravani

Varma

2022

Marine Drugs

View full text Add to dashboard Cite

Alginates have been widely explored due to their salient advantages of hydrophilicity, biocompatibility, mucoadhesive features, bioavailability, environmentally-benign properties, and cost-effectiveness. They are applied for designing micro- and nanosystems for controlled and targeted drug delivery and cancer therapy as alginate biopolymers find usage in encapsulating anticancer drugs to improve their bioavailability, sustained release, pharmacokinetics, and bio-clearance. Notably, these nanomaterials can be applied for photothermal, photodynamic, and chemodynamic therapy of cancers/tumors. Future explorations ought to be conducted to find novel alginate-based (nano)systems for targeted cancer therapy using advanced drug delivery techniques with benefits of non-invasiveness, patient compliance, and convenience of drug administration. Thus, some critical parameters such as mucosal permeability, stability in the gastrointestinal tract environment, and drug solubility ought to be considered. In addition, the comprehensive clinical translational studies along with the optimization of synthesis techniques still need to be addressed. Herein, we present an overview of the current state of knowledge and recent developments pertaining to the applications of alginate-based micro- and nanosystems for targeted cancer therapy based on controlled drug delivery, photothermal therapy, and chemodynamic/photodynamic therapy approaches, focusing on important challenges and future directions.

show abstract

“…In addition, there are portions of the gastrointestinal tract, such as the intestines, liver and kidneys, with an increased expression of the P-glycoprotein (multidrug efflux pump), also known as the multidrug resistance protein, which contributes to the limited bioavailability of paclitaxel [ 107 ]. There have been numerous efforts to develop nanocarriers based on nanoclay for the administration of paclitaxel to cancer cells [ 108 ]. In this regard, Dong et al have created a bioadhesive nano system for the oral administration of paclitaxel.…”

Section: Nano-clays In the Treatment Of Cancermentioning

confidence: 99%

Nano-Clays for Cancer Therapy: State-of-the Art and Future Perspectives

Persano

Leporatti

2022

JPM

View full text Add to dashboard Cite

To date, cancer continues to be one of the deadliest diseases. Current therapies are often ineffective, leading to the urgency to develop new therapeutic strategies to improve treatments. Conventional chemotherapeutics are characterized by a reduced therapeutic efficacy, as well as them being responsible for important undesirable side effects linked to their non-specific toxicity. In this context, natural nanomaterials such as clayey mineral nanostructures of various shapes (flat, tubular, spherical and fibrous) with adjustable physico-chemical and morphological characteristics are emerging as systems with extraordinary potential for the delivery of different therapeutic agents to tumor sites. Thanks to their submicron size, high specific surface area, high adsorption capacity, chemical inertia and multilayer organization of 0.7 to 1 nm-thick sheets, they have aroused considerable interest among the scientific community as nano systems that are highly biocompatible in cancer therapy. In oncology, the nano-clays usually studied are halloysite, bentonite, laponite, kaolinite, montmorillonite and sepiolite. These are multilayered minerals that can act as nanocarriers (with a drug load generally between 1 and 10% by weight) for improved stabilization, efficient transport and the sustained and controlled release of a wide variety of anticancer agents. In particular, halloysite, montmorillonite and kaolinite are used to improve the dissolution of therapeutic agents and to delay and/or direct their release. In this review, we will examine and expose to the scientific community the extraordinary potential of nano-clays as unique crystalline systems in the treatment of cancer.

show abstract

Nanocarriers for anticancer drugs: Challenges and perspectives

Cited by 36 publications

References 127 publications

Codelivery of Phytochemicals with Conventional Anticancer Drugs in Form of Nanocarriers

Codelivery of Phytochemicals with Conventional Anticancer Drugs in Form of Nanocarriers

Alginate-Based Micro- and Nanosystems for Targeted Cancer Therapy

Nano-Clays for Cancer Therapy: State-of-the Art and Future Perspectives

Contact Info

Product

Resources

About